Last10K.com

Supernus Pharmaceuticals Inc (SUPN) SEC Filing 8-K Material Event for the period ending Wednesday, October 24, 2018

Supernus Pharmaceuticals Inc

HISTORY TOOLS
CIK: 1356576 Ticker: SUPN

Exhibit 99.1

 

 

Supernus to Host Third Quarter 2018 Earnings Conference Call

 

ROCKVILLE, Md., October 24, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the third quarter of 2018 after 5:00 p.m. ET on Tuesday, November 6, 2018.

 

Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter 2018 business results on Wednesday, November 7, 2018 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.

 

A live webcast will be available at www.supernus.com.

 

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

 

Conference dial-in:

(877) 288-1043

International dial-in:

(970) 315-0267

Conference ID:

2697616

Conference Call Name:

Supernus Pharmaceuticals Third Quarter 2018 Earnings

 

Conference Call

 

Following the live call, a replay will be available on the Company’s website under the ‘Investors’ section. The webcast will be available on the Company’s website for 60 days following the live call.

 

About Supernus Pharmaceuticals, Inc.

 

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD, and Oxtellar XR for the treatment of bipolar.

 

CONTACTS:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

 

or

 

INVESTOR CONTACT:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

 

View differences made from one to another to evaluate Supernus Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Supernus Pharmaceuticals Inc.

Continue

Assess how Supernus Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Supernus Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Supernus Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: SUPN
CIK: 1356576
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-063964
Submitted to the SEC: Thu Oct 25 2018 4:54:48 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations
Events:
  1. Earnings Release
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/supn/0001104659-18-063964.htm